Meng Ye

Dr. Meng Ye


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 February 2022 in Gene
Verified
Journal Article
Closed access
YGYidong Ge
Yidong Ge
JJJiabei Jin
Jiabei Jin
JLJinyun Li
Jinyun Li
MYMeng Ye
Meng Ye
XJxiaofeng jin
xiaofeng jin

25 October 2023 in Oncology Letters
Verified
Journal Article
Open access
PDF file
YGYidong Ge
Yidong Ge
XNXiaoqi Ni
Xiaoqi Ni
JLJingyun Li
Jingyun Li
MYMeng Ye
Meng Ye
XJxiaofeng jin
xiaofeng jin
Endometrial carcinoma (EC) is a group of endometrial epithelial malignancies, most of which are adenocarcinomas and occur in perimenopausal and postmenopausal women. It is one of the most common carcinomas of the female reproductive system. It has been shown that the occurrence and development of EC is closely associated with the interaction between estrogen (estradiol, E2) and estrogen receptors (ERs), particularly ERα. As a key nuclear transcription factor, ERα is a carcinogenic factor in EC. Its interactions with upstream and downstream effectors and co‑regulators have important implications for the proliferation, metastasis, invasion and inhibition of apoptosis of EC. In the present review, the structure of ERα and the regulation of ERα in multiple dimensions are described. In addition, the classical E2/ERα signaling pathway and the crosstalk between ERα and other EC regulators are elucidated, as well as the therapeutic targeting of ERα, which may provide a new direction for clinical applications of ERα in the future.

22 September 2023 in Molecular Medicine Reports
Verified
Journal Article
Open access
PDF file
ZZZiqing Zhan
Ziqing Zhan
MYMeng Ye
Meng Ye
XJxiaofeng jin
xiaofeng jin
FLOT1, a scaffold protein of lipid rafts, is involved in several biological processes, including lipid raft protein‑­dependent or clathrin‑independent endocytosis, and the formation of hippocampal synapses, amongst others. Increasing evidence has shown that FLOT1 can function as both a cancer promoter and cancer suppressor dependent on the type of cancer. FLOT1 can affect the occurrence and development of several types of cancer by affecting epithelial‑mesenchymal transition, proliferation of cancer cells, and relevant signaling pathways, and is regulated by long intergenic non‑coding RNAs or microRNAs. In the nervous system, overexpression or abnormally low expression of FLOT1 may lead to the occurrence of neurological diseases, such as Alzheimer's disease, Parkinson's disease, major depressive disorder and other diseases. Additionally, it is also associated with dilated cardiomyopathy, pathogenic microbial infection, diabetes‑related diseases, and gynecological diseases, amongst other diseases. In the present review, the structure and localization of FLOT1, as well as the physiological processes it is involved in are reviewed, and then the upstream and downstream regulation of FLOT1 in human disease, particularly in different types of cancer and neurological diseases are discussed, with a focus on potentially targeting FLOT1 for the clinical treatment of several diseases.

14 May 2022 in Gene
Verified
Journal Article
Closed access
FZFengguang Zhai
Fengguang Zhai
JLJingyun Li
Jingyun Li
MYMeng Ye
Meng Ye
XJxiaofeng jin
xiaofeng jin

17 October 2022 in Gene
Verified
Journal Article
Closed access
YZYeling Zhong
Yeling Zhong
JLJinyun Li
Jinyun Li
MYMeng Ye
Meng Ye
XJxiaofeng jin
xiaofeng jin

1 January 2022 in Gene
Verified
Journal Article
Closed access
KLKailang Li
Kailang Li
JLJinyun Li
Jinyun Li
MYMeng Ye
Meng Ye
XJxiaofeng jin
xiaofeng jin